Kidney and Urinary Tract Signs and Symptoms with MCC DRG Reimbursement

DRG 695 covers inpatient admissions for kidney and urinary tract signs and symptoms when a Major Complication or Comorbidity is present, reflecting higher clinical severity. This grouping matters for inpatient reimbursement because Major Complication or Comorbidity status increases expected resource use and affects Medicare payment under the prospective payment system.

DRG 695 Overview

DRG 695 covers inpatient cases with signs and symptoms related to the kidney and urinary tract when a Major Complication or Comorbidity is present, typically including presentations such as acute renal failure, severe hematuria, or obstructive uropathy with systemic impact. This Diagnosis-Related Group groups patients by clinical similarity and resource use, influencing payment under Medicare inpatient prospective payment systems. Presence of a Major Complication or Comorbidity elevates the expected resource intensity and thus the payment relative to lower-severity groupings. Accurate coding of diagnosis and documented severity is central to assignment to this Diagnosis-Related Group and subsequent Medicare reimbursement.

Acute diagnostic and management trials for obstructive uropathy and acute kidney injury in hospitalized adults: studies in this area test rapid diagnostic pathways, timing and selection of urgent interventions (such as urinary drainage techniques) and bundled care protocols for patients admitted with flank pain, anuria, or rising creatinine due to obstructing stones, prostatic obstruction, or infectious causes. The patient population includes adults with acute kidney or urinary tract signs and symptoms complicated by physiologic instability or laboratory markers meeting MCC criteria; endpoints focus on time-to-relief of obstruction, renal function recovery, need for dialysis, and length of stay. This research is highly relevant to providers and payers because early diagnostic algorithms and optimized acute management can reduce progression to severe renal injury, shorten hospital stays, and lower costs associated with ICU care or renal replacement therapy.
Comparative effectiveness trials of inpatient antimicrobial and sepsis management strategies for complicated urinary tract infections and urosepsis: randomized or pragmatic studies compare different empiric and stewardship-informed antibiotic regimens, source-control timing, and sepsis bundle components specifically in patients whose urinary tract infection presents with organ dysfunction or other major complications. The population studied are hospitalized patients with complicated UTI/pyelonephritis or urosepsis meeting MCC-level severity, with outcomes including clinical resolution, antimicrobial resistance emergence, adverse events, and resource utilization. Findings inform clinicians and payers about which evidence-based inpatient approaches offer the best balance of clinical efficacy, reduced resistance, and lower downstream costs from readmissions or prolonged therapy.
Post-discharge outcomes and transitional care studies focused on renal recovery, readmission reduction, and care coordination after hospitalization for kidney/urinary tract emergencies: observational cohorts and interventional trials evaluate discharge planning models, early nephrology follow-up, home-based monitoring of renal function, and patient education to prevent rehospitalization and chronic kidney disease progression among survivors of severe inpatient episodes. These studies enroll patients discharged after an admission characterized by major complications (MCC), tracking renal function trajectories, dialysis dependence, readmission rates, and outpatient resource use. Payors and health systems use this evidence to design post-acute care pathways that improve long-term outcomes, reduce readmissions, and optimize reimbursement through bundled or value-based payment models.

Acute diagnostic and management trials for obstructive uropathy and acute kidney injury in hospitalized adults: studies in this area test rapid diagnostic pathways, timing and selection of urgent interventions (such as urinary drainage techniques) and bundled care protocols for patients admitted with flank pain, anuria, or rising creatinine due to obstructing stones, prostatic obstruction, or infectious causes. The patient population includes adults with acute kidney or urinary tract signs and symptoms complicated by physiologic instability or laboratory markers meeting MCC criteria; endpoints focus on time-to-relief of obstruction, renal function recovery, need for dialysis, and length of stay. This research is highly relevant to providers and payers because early diagnostic algorithms and optimized acute management can reduce progression to severe renal injury, shorten hospital stays, and lower costs associated with ICU care or renal replacement therapy.
Comparative effectiveness trials of inpatient antimicrobial and sepsis management strategies for complicated urinary tract infections and urosepsis: randomized or pragmatic studies compare different empiric and stewardship-informed antibiotic regimens, source-control timing, and sepsis bundle components specifically in patients whose urinary tract infection presents with organ dysfunction or other major complications. The population studied are hospitalized patients with complicated UTI/pyelonephritis or urosepsis meeting MCC-level severity, with outcomes including clinical resolution, antimicrobial resistance emergence, adverse events, and resource utilization. Findings inform clinicians and payers about which evidence-based inpatient approaches offer the best balance of clinical efficacy, reduced resistance, and lower downstream costs from readmissions or prolonged therapy.
Post-discharge outcomes and transitional care studies focused on renal recovery, readmission reduction, and care coordination after hospitalization for kidney/urinary tract emergencies: observational cohorts and interventional trials evaluate discharge planning models, early nephrology follow-up, home-based monitoring of renal function, and patient education to prevent rehospitalization and chronic kidney disease progression among survivors of severe inpatient episodes. These studies enroll patients discharged after an admission characterized by major complications (MCC), tracking renal function trajectories, dialysis dependence, readmission rates, and outpatient resource use. Payors and health systems use this evidence to design post-acute care pathways that improve long-term outcomes, reduce readmissions, and optimize reimbursement through bundled or value-based payment models.

OpenPayer

Summary & Overview

Kidney and Urinary Tract Signs and Symptoms with MCC: Inpatient Reimbursement Overview

DRG 695 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes